Tyra reported a Q4 2025 net loss of 33834000 driven by 36516000 in total operating expenses, reflecting continued investment in dabogratinib clinical development. Cash, cash equivalents and marketable securities totaled 256003000 at quarter end, providing runway through at least 2027.

In Q2 2025, Tyra Biosciences posted a net loss of $18.1 million with no revenue, reflecting ongoing investment in its clinical-stage precision oncology programs. R&D expenses totaled $14.4 million, and the company maintained a strong cash position of $275.1 million.

Tyra Biosciences, Inc. reported a net loss of $28.1 million for the three months ended March 31, 2025, compared to a net loss of $18.2 million for the same period in 2024. This increased loss was primarily due to a significant rise in total operating expenses, which reached $31.85 million, up from $22.32 million in the prior year. The company's cash, cash equivalents, and marketable securities stood at $318.9 million as of March 31, 2025, which is expected to fund operations through at least 2027.

Tyra Biosciences reported a net loss of $25.571 million for Q4 2024, with total assets of $363.558 million and cash and cash equivalents of $91.966 million. The company advanced TYRA-300 into three Phase 2 studies and cleared INDs for SURF302 and BEACH301, demonstrating significant clinical progress.

Tyra Biosciences reported its Q3 2024 financial results, featuring positive interim data for TYRA-300 in mUC, progress in expanding TYRA-300 development into NMIBC, clearance for a Phase 2 achondroplasia study, and the appointment of Doug Warner as CMO. The company's cash reserves are expected to last through at least 2026.

Tyra Biosciences reported a net loss of $18.7 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $373.8 million as of June 30, 2024.

Tyra Biosciences reported a net loss of $18.2 million for the first quarter of 2024. The company's research and development expenses were $17.2 million, and general and administrative expenses were $5.1 million. As of March 31, 2024, Tyra had cash, cash equivalents, and marketable securities of $382.5 million.

Tyra Biosciences reported a net loss of $22.8 million for the fourth quarter of 2023, compared to a net loss of $12.9 million for the same period in 2022. Research and development expenses were $20.7 million, and general and administrative expenses were $5.0 million for the quarter. The company's cash, cash equivalents, and marketable securities totaled $203.5 million as of December 31, 2023, which is expected to support operations through at least 2026, especially after the $200 million PIPE in Q1 2024.

Tyra Biosciences reported a net loss of $21.2 million for the third quarter of 2023 and highlighted the advancement of TYRA-300 in the SURF301 oncology study, positive preclinical data for achondroplasia, and the expected initiation of the TYRA-200 Phase 1 study by the end of 2023. The company's cash and cash equivalents totaled $215.7 million as of September 30, 2023.

Tyra Biosciences reported a net loss of $13.3 million for the second quarter of 2023 and had cash and cash equivalents of $232.4 million as of June 30, 2023. The company is advancing its pipeline, including TYRA-300 and TYRA-200, and received Orphan Drug Designation for TYRA-300 in achondroplasia.

Tyra Biosciences reported a net loss of $11.9 million for the first quarter of 2023, with a strong cash position of $241.7 million as of March 31, 2023. The company continued to advance its SURF301 Phase 1/2 clinical study for oncology and expanded the development of TYRA-300 into achondroplasia. The IND for TYRA-200 was cleared, with a Phase 1 study on track for the second half of 2023.

Tyra Biosciences reported a net loss of $12.9 million for the fourth quarter of 2022. The company's cash and cash equivalents stood at $251.2 million as of year-end 2022.

Tyra Biosciences reported a net loss of $12.5 million for Q3 2022, with cash and cash equivalents totaling $263.2 million as of September 30, 2022. The company's pipeline development remains on track, including the planned initiation of the SURF301 study and the IND filing for TYRA-200 by the end of 2022.

Tyra Biosciences reported a net loss of $15.1 million for the second quarter of 2022. The FDA cleared the company to proceed with its SURF301 study of TYRA-300, and the IND for TYRA-200 is on track to be filed in the second half of 2022. The company had cash and cash equivalents of $275.1 million as of Q2 2022.

Tyra Biosciences reported a net loss of $14.8 million for the first quarter of 2022, with cash and cash equivalents totaling $292.5 million as of March 31, 2022. The company is on track to file INDs for TYRA-300 and TYRA-200 in 2022 and is progressing its pipeline.

Tyra Biosciences reported a net loss of $9.9 million for the fourth quarter of 2021, compared to a net loss of $3.7 million for 2020. The company's research and development expenses were $7.2 million for the quarter, and they ended the year with $302.2 million in cash and cash equivalents.